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Adoptive transfer of chimeric antigen receptor (CAR)-
engineered T cells has demonstrated robust and durable
clinical efficacy in patients with CD19+ B cell malignan-
cies. Broader application of this approach to brain and
other advanced solid tumors is an immediate goal for
the field and is presently under intense investigation. In
2014, 40,000 individuals in the U.S. alone succumbed to
breast cancer, primarily as a result of metastatic disease.
Approximately 30 percent of breast cancer patients
carry an amplification of the HER2 gene and/or HER2
over-expression, which confers a particularly poor prog-
nosis. Among the most common sites of HER2-positive
breast cancer metastases is the brain. For patients with
breast cancer that has metastasized to the brain, the
1-year survival rate is a dismal 20 percent. Despite clini-
cal successes in both preventing relapse and treating
systemic disease with HER2-targeted therapies, the cur-
rently available agents are only modestly effective in
managing brain metastasis. Our group has demonstrated
safety and transient anti-tumor responses in two U.S.
FDA-authorized Phase I clinical trials evaluating local
intracranial adoptive transfer of CAR T cells in glioma
patients. Our current project builds on this clinical
experience with locally administered CAR T cells that
specifically target HER2 for the treatment of breast-to-
brain metastasis.
Our lab has initiated design and testing of CAR T cell
therapy targeting HER2 based on an scFv derived from
trastuzumab. We anticipate that local intracranial deliv-
ery will enhance therapeutic response, while reducing
the likelihood of off-tumor systemic toxicities as
previously observed. Importantly, HER2 expression in
normal brain tissue is limited, supporting HER2 as a
therapeutic target in brain metastasis. Our innovative
CAR T cell platform focuses on engineering central
memory T cells (Tcm) for therapeutic application, with the
intent of improving persistence of T cells after infusion, a
critical parameter correlated with ultimate therapeutic
success. Herein, we have evaluated several HER2-CAR
constructs incorporating either the CD28 or 4-1BB
co-stimulatory domain using both in vitro T cell functional
assays as well as orthotopic patient-derived xenograft mod-
els of breast-to-brain metastasis. While HER2-28z and
HER2-BBz CAR T cells similarly kill HER2+ breast cancer
cells in vitro, BBz CARs demonstrate lower induction of
the exhaustion marker PD-1 and proliferate better compare
with 28z CARs. Both HER2-CARs similarly lead to tumor
eradication and prolonged survival. Based on these data, we
have successfully developed HER2-specific CAR T cells,
and plan to clinically develop these CARs for the treatment
of HER2+ metastatic disease.
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